Proteasome Inhibitor
Ixazomib + Cyclophosphamide + Dexamethasone for Multiple Myeloma
This trial is testing cyclophosphamide given with ixazomib citrate and dexamethasone to see what effects, good and bad, it has in treating patients with previously untreated multiple myeloma or light chain amyloidosis.
Monoclonal Antibodies
CAEL-101 for Amyloidosis
This trial is testing a new treatment for AL amyloidosis, which is a disease where abnormal proteins misfold and create free light chains that build up in organs. The new treatment, CAEL-101, is a monoclonal antibody that removes AL amyloid deposits from tissues and organs. The trial will test whether CAEL-101 improves overall survival and is safe and well tolerated in patients with stage IIIb AL amyloidosis.
Popular Filters
Trials for Amyloidosis Patients
Monoclonal Antibodies
Daratumumab Combination Therapy for Amyloidosis
This trial tests a combination of four drugs on patients with a specific heart-related disease. The drugs work together to attack abnormal cells and reduce inflammation. The study aims to ensure the treatment is safe for the heart and understand how it behaves in different racial and ethnic groups.
Monoclonal Antibodies
Belantamab Mafodotin for AL Amyloidosis
This trial is testing Belantamab mafodotin, a drug that targets and kills harmful cells, on patients with Relapsed Refractory AL Amyloidosis who have not responded to other treatments. The drug works by attaching to bad cells and delivering a toxic substance to eliminate them. Belantamab mafodotin is a newly approved treatment for certain types of cancer.
Trials for ATTR Patients
Monoclonal Antibodies
Daratumumab Combination Therapy for Amyloidosis
This trial tests a combination of four drugs on patients with a specific heart-related disease. The drugs work together to attack abnormal cells and reduce inflammation. The study aims to ensure the treatment is safe for the heart and understand how it behaves in different racial and ethnic groups.
Monoclonal Antibodies
Belantamab Mafodotin for AL Amyloidosis
This trial is testing Belantamab mafodotin, a drug that targets and kills harmful cells, on patients with Relapsed Refractory AL Amyloidosis who have not responded to other treatments. The drug works by attaching to bad cells and delivering a toxic substance to eliminate them. Belantamab mafodotin is a newly approved treatment for certain types of cancer.
Phase 3 Trials
Monoclonal Antibodies
CAEL-101 for Amyloidosis
This trial is testing CAEL-101, a special medicine, in patients with severe AL amyloidosis. The goal is to see if it helps clear harmful protein deposits from their organs and improves their survival. The study will compare CAEL-101 with standard treatments.
Trials With No Placebo
Monoclonal Antibodies
Daratumumab Combination Therapy for Amyloidosis
This trial tests a combination of four drugs on patients with a specific heart-related disease. The drugs work together to attack abnormal cells and reduce inflammation. The study aims to ensure the treatment is safe for the heart and understand how it behaves in different racial and ethnic groups.
Monoclonal Antibodies
Belantamab Mafodotin for AL Amyloidosis
This trial is testing Belantamab mafodotin, a drug that targets and kills harmful cells, on patients with Relapsed Refractory AL Amyloidosis who have not responded to other treatments. The drug works by attaching to bad cells and delivering a toxic substance to eliminate them. Belantamab mafodotin is a newly approved treatment for certain types of cancer.
Frequently Asked Questions
Introduction to al amyloidosis
What are the top hospitals conducting al amyloidosis research?
In the quest to find effective treatments for al amyloidosis, several top hospitals across the United States are leading the way in conducting groundbreaking clinical trials. One such institution is the Karmanos Cancer Institute located in Detroit. With a commendable six active trials and a total of 13 trials dedicated to al amyloidosis, this institute has been at the forefront of research since their first recorded trial in 2012. In Portland, Oregon Health & Science University is also making significant strides with five ongoing clinical trials and an impressive track record of 15 completed studies since initiating their first al amyloidosis trial in 2013.
Further contributing to this important area of study is Boston's esteemed Dana-Farber Cancer Institute. They currently have five active al amyloidosis trials and hold a history of seven previously conducted studies dating back to their pioneering investigation on this condition in 1996. Meanwhile, Tufts Medical Center, also located in Boston, boasts four active trials and an impressive tally of 22 all-time al amyloidosis trials since embarking on their initial research efforts in 2010.
Lastly but certainly not least, The Ohio State University situated in Columbus brings its expertise into play with four ongoing clinical tests focused on al amyloidosis while having accomplished four previous investigations within its relatively recent emergence onto this scene; theirs can be traced back only as far as recording its inaugural trial related to this condition just four years ago –in2017
These top hospitals are not only delivering hope for individuals affected by al amyloidosis but also driving progress towards better understanding and treatment options for this rare disease nationwide. Their collective efforts embody dedication and determination that pave the path toward breakthroughs ultimately improving countless lives around the country
Which are the best cities for al amyloidosis clinical trials?
In the realm of al amyloidosis clinical trials, several cities have emerged as prominent hubs for research and investigation. Boston, Massachusetts leads the pack with 23 active trials exploring treatments such as CAEL-101, Daratumumab, and Belantamab mafodotin. New york City follows closely behind with 18 ongoing studies investigating similar interventions like CAEL-101 and Daratumumab. Detroit, Michigan also plays a significant role in al amyloidosis research with 11 active trials focused on treatment options including CAEL-101 and Tracking Dietary/Supplement Intake through smartphone applications. Lastly, Cleveland, Ohio and Duarte, California are actively involved in this field as well with respective portfolios of 9 and 8 ongoing trials studying interventions like CAEL-101 and Venetoclax. These cities serve as crucial centers for advancing our understanding and improving outcomes for individuals diagnosed with al amyloidosis through rigorous clinical trial endeavors.
Which are the top treatments for al amyloidosis being explored in clinical trials?
Exciting progress is being made in clinical trials for the treatment of AL amyloidosis. CAEL-101 stands out as a leading contender, currently undergoing three active trials dedicated to this condition since its introduction in 2020. Another promising option is daratumumab, with two ongoing trials and a total of eleven all-time al amyloidosis studies since 2016. Additionally, ixazomib and venetoclax show great potential, each participating in two active trials and contributing to six all-time al amyloidosis studies (ixazomib) and four (venetoclax) since their respective debut dates. These groundbreaking therapies offer hope for patients battling AL amyloidosis, bringing us closer to improved outcomes against this challenging disease.
What are the most recent clinical trials for al amyloidosis?
Exciting advancements are being made in the field of AL amyloidosis, with recent clinical trials offering hope for improved treatment options. Venetoclax has shown promising results in Phase 1 and Phase 2 trials, making it a potential breakthrough therapy for AL amyloidosis. Another trial focused on the use of daratumumab as part of Arm I treatment, showcasing its efficacy in managing this condition. Additionally, patients with ATTR-CM have been included in Phase 2 trials to evaluate their response to different interventions. With ongoing research and development efforts, these studies offer promise for individuals living with AL amyloidosis and may lead to significant improvements in patient outcomes.
What al amyloidosis clinical trials were recently completed?
In the realm of al amyloidosis, several noteworthy clinical trials have recently concluded, paving the way for potential advancements in treatments. In March 2022, Columbia University wrapped up a trial exploring the efficacy of Empagliflozin in addressing this complex disease. Notably, Ionis Pharmaceuticals also completed their Eplontersen trial back in January 2020, while Eidos Therapeutics brought their acoramidis study to completion in March 2019. These significant research endeavors demonstrate ongoing efforts to enhance our understanding and management of al amyloidosis and bring hope to those affected by this challenging condition.